Updates are available Correction dated 2020-09-04

Article History

Received: 14 February 2020

Accepted: 28 May 2020

First Online: 9 July 2020

Change Date: 4 September 2020

Change Type: Correction

Change Details: An amendment to this paper has been published and can be accessed via the original article.

Ethics approval and consent to participate

: This study was conducted as a multi-center, open-label, prospective, non-interventional study, conducted in accordance with the Ministerial Ordinance on Good Post-Marketing Study Practice (Ministry of Health, Labour and Welfare Ordinance No. 171, December 20, 2004). The study protocol was review and approved by the Japanese regulatory authority before initiation. This study did not undergo review by the ethics committee of the participating medical institutions or the informed consent procedure, unless such procedures were required by individual participating medical institution.

: Not applicable.

: HT has received research funding from Kowa, Santen Pharmaceutical and Senju Pharmaceutical, consulting fees from Kowa, Aerie Pharmaceuticals, Inc., Santen Pharmaceutical and Wakamoto Pharmaceutical, and honoraria for lectures from Kowa, Senju Pharmaceutical, Santen Pharmaceutical, Otsuka Pharma Co. Ltd., Pfizer, Rohto Pharmaceutical, Wakamoto Pharmaceutical, HOYA Corporation, Mitsubishi Tanabe Pharma, Glaukos Japan and Novartis Pharma. T Kakuda, TS, T Kanno and RG are employees of Kowa Co., Ltd.